$16.94
1.77% today
NYSE, Sep 24, 05:52 pm CET
ISIN
US49177J1025
Symbol
KVUE

Kenvue Stock price

$17.24
-3.95 18.64% 1M
-6.13 26.23% 6M
-4.11 19.25% YTD
-5.78 25.11% 1Y
-9.66 35.91% 3Y
-9.66 35.91% 5Y
-9.66 35.91% 10Y
-9.66 35.91% 20Y
NYSE, Closing price Tue, Sep 23 2025
+0.27 1.59%
ISIN
US49177J1025
Symbol
KVUE
Index

Key metrics

Basic
Market capitalization
$33.1b
Enterprise Value
$40.6b
Net debt
$7.5b
Cash
$1.1b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
23.3 | 16.2
P/S
2.2 | 2.1
EV/Sales
2.7 | 2.6
EV/FCF
24.9
P/B
3.1
Dividends
DPS
$0.81
Yield 1Y | 5Y
4.7% | 1.1%
Growth 1Y | 5Y
102.5% | -
Payout 1Y | 3Y
150.0% | 47.6%
Increased
2 Years
Financials (TTM | estimate)
Revenue
$15.1b | $15.4b
EBITDA
$3.2b | $3.7b
EBIT
$2.6b | $3.1b
Net Income
$1.4b | $2.0b
Free Cash Flow
$1.6b
Growth (TTM | estimate)
Revenue
-2.2% | -0.1%
EBITDA
-8.3% | 3.9%
EBIT
-9.8% | 3.9%
Net Income
26.7% | 98.1%
Free Cash Flow
-7.8%
Margin (TTM | estimate)
Gross
58.3%
EBITDA
21.4% | 24.0%
EBIT
17.4%
Net
9.4% | 13.2%
Free Cash Flow
10.8%
Financial Health
Equity Ratio
37.8%
Return on Equity
10.7%
ROCE
12.5%
ROIC
8.1%
Debt/Equity
0.8
More
EPS
$0.7
FCF per Share
$0.9
Short interest
3.0%
Employees
22k
Rev per Employee
$700.0k
Show more

Is Kenvue a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Kenvue Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Kenvue forecast:

9x Buy
38%
14x Hold
58%
1x Sell
4%

Analyst Opinions

24 Analysts have issued a Kenvue forecast:

Buy
38%
Hold
58%
Sell
4%

Financial data from Kenvue

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15,141 15,141
2% 2%
100%
- Direct Costs 6,322 6,322
3% 3%
42%
8,819 8,819
2% 2%
58%
- Selling and Administrative Expenses 5,758 5,758
2% 2%
38%
- Research and Development Expense 393 393
6% 6%
3%
3,243 3,243
8% 8%
21%
- Depreciation and Amortization 610 610
1% 1%
4%
EBIT (Operating Income) EBIT 2,633 2,633
10% 10%
17%
Net Profit 1,418 1,418
27% 27%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Kenvue directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kenvue Stock News

Positive
Fast Company
about 17 hours ago
Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and, in some cases, discredited ties between Tylenol, vaccines, and autism.
Neutral
Investopedia
about 21 hours ago
Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.
Negative
Fast Company
about 22 hours ago
President Donald Trump on Monday used the platform of the presidency to promote unproven and in some cases discredited ties between Tylenol, vaccines and autism as his administration announced a wide-ranging effort to study the causes of the complex brain disorder.“Don't take Tylenol,” Trump instructed pregnant women around a dozen times during the unwieldy White House news conference, also urg...
More Kenvue News

Company Profile

Kenvue, Inc. engages in the provision of healthcare products services. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment includes oral care, baby care, women’s health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Head office United States
CEO Thibaut Mongon
Employees 22,000
Website www.kenvue.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today